+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924699
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Extensive Stage Small Cell Lung Cancer Market grew from USD 4.75 billion in 2023 to USD 5.40 billion in 2024. It is expected to continue growing at a CAGR of 12.63%, reaching USD 10.92 billion by 2030.

The scope of research and analysis of the market for treatments targeting Extensive Stage Small Cell Lung Cancer (ES-SCLC) involves evaluating various therapeutic solutions, analyzing trends in drug development, and understanding emerging technologies, aiming to optimize and enhance patient outcomes. The necessity and application of such treatments are critical due to the aggressive nature of ES-SCLC and its high mortality rate. Innovations in immunotherapy, targeted therapies, and combination regimens form the core of the end-use scope, targeting improved survival rates and quality of life for patients. Key growth factors influencing this market include advancements in biotechnology, increased R&D investments, and rising awareness regarding personalized medicine. Significant opportunities lie in the development of novel biomarkers and gene therapies, as well as enhanced diagnostic tools for early and accurate detection. Collaborations between pharmaceutical companies and research institutes can further facilitate innovative exploration. However, the market faces challenges such as high costs of treatment, limited availability of advanced therapies in emerging regions, and regulatory hurdles that can delay the approval of new drugs. There is also a need to address the resistance mechanisms that cancer cells develop against current treatments. For businesses, there are potential areas of innovation such as the exploration of novel therapeutic targets, leveraging AI for drug discovery processes, and developing partnerships for clinical research. Companies can differentiate themselves by focusing on patient-centric approaches and improving accessibility to novel therapeutics. The nature of the market is competitive and rapidly evolving, demanding continuous innovation and adaptation. Emphasis on multi-platform treatment approaches that combine existing and innovative therapies might provide enhanced efficacy and patient outcomes, thus positioning companies favorably within the market landscape. Businesses should stay abreast of regulatory changes, actively engage in clinical trials, and prioritize sustainable practices to leverage growth opportunities effectively.

Understanding Market Dynamics in the Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increase in prevalence of extensive stage small cell lung cancer across the globe
    • Growing awareness regarding enhanced health care
    • Rising government initiatives for extensive stage small cell lung cancer treatment
  • Market Restraints
    • Huge availability of the generic drugs
  • Market Opportunities
    • Increasing funding in the field of research and development of new treatment
    • Technological advancement in the extensive stage small cell lung cancer screening procedures
  • Market Challenges
    • Risk of side effects of radiation and chemotherapy

Exploring Porter’s Five Forces for the Extensive Stage Small Cell Lung Cancer Market

Porter’s Five Forces framework further strengthens the insights of the Extensive Stage Small Cell Lung Cancer Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Extensive Stage Small Cell Lung Cancer Market

External macro-environmental factors deeply influence the performance of the Extensive Stage Small Cell Lung Cancer Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Extensive Stage Small Cell Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly & Company Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck KGaA, Nektar Therapeutics, Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Extensive Stage Small Cell Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Modalities
    • Chemotherapy
    • Combination Therapies
    • Immunotherapy
    • Radiation Therapy
    • Targeted Therapies
  • Drug Type
    • Atezolizumab
    • Durvalumab
    • Etoposide
    • Lurbinectedin
    • Methotrexate
    • Pembrolizumab
    • Topotecan
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of extensive stage small cell lung cancer across the globe
5.1.1.2. Growing awareness regarding enhanced health care
5.1.1.3. Rising government initiatives for extensive stage small cell lung cancer treatment
5.1.2. Restraints
5.1.2.1. Huge availability of the generic drugs
5.1.3. Opportunities
5.1.3.1. Increasing funding in the field of research and development of new treatment
5.1.3.2. Technological advancement in the extensive stage small cell lung cancer screening procedures
5.1.4. Challenges
5.1.4.1. Risk of side effects of radiation and chemotherapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Extensive Stage Small Cell Lung Cancer Market, by Treatment Modalities
6.1. Introduction
6.2. Chemotherapy
6.3. Combination Therapies
6.4. Immunotherapy
6.5. Radiation Therapy
6.6. Targeted Therapies
7. Extensive Stage Small Cell Lung Cancer Market, by Drug Type
7.1. Introduction
7.2. Atezolizumab
7.3. Durvalumab
7.4. Etoposide
7.5. Lurbinectedin
7.6. Methotrexate
7.7. Pembrolizumab
7.8. Topotecan
8. Extensive Stage Small Cell Lung Cancer Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Extensive Stage Small Cell Lung Cancer Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Extensive Stage Small Cell Lung Cancer Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Extensive Stage Small Cell Lung Cancer Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Extensive Stage Small Cell Lung Cancer Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 2. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2030 (%)
FIGURE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET DYNAMICS
TABLE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY LURBINECTEDIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TOPOTECAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 42. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 46. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 64. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 68. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 76. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 100. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 113. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 117. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 121. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 125. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 129. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 137. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 149. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 153. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 157. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 173. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 185. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 197. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Extensive Stage Small Cell Lung Cancer Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly & Company Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Nektar Therapeutics
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.92 Billion
Compound Annual Growth Rate12.6%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Extensive Stage Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Extensive Stage Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 131 Pages
  • Global
From
Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024 - Product Image

Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market by Cancer Type, Drug Class, Distribution Channel - Global Forecast 2025-2030 - Product Image

Non-small Cell Lung Cancer Therapeutics Market by Cancer Type, Drug Class, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Lung Cancer Drugs Market by Disease, Molecule, Distribution Channel - Global Forecast 2025-2030 - Product Image

Lung Cancer Drugs Market by Disease, Molecule, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.